Trials / Completed
CompletedNCT02398188
Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)
A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat in Non-Obese Subjects
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 793 (actual)
- Sponsor
- Evofem Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LIPO-202 | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-04-09
- Primary completion
- 2015-10-29
- Completion
- 2015-10-29
- First posted
- 2015-03-25
- Last updated
- 2019-01-07
- Results posted
- 2019-01-07
Locations
35 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02398188. Inclusion in this directory is not an endorsement.